Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBT (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of EBT readings, the most recent being $239.4 million for Q4 2025.

  • On a quarterly basis, EBT rose 47.23% to $239.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $705.4 million, a 45.14% increase, with the full-year FY2025 number at $705.4 million, up 45.14% from a year prior.
  • EBT hit $239.4 million in Q4 2025 for Neurocrine Biosciences, down from $291.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $291.8 million in Q3 2025 to a low of -$103.3 million in Q1 2023.
  • Median EBT over the past 5 years was $98.2 million (2022), compared with a mean of $91.9 million.
  • Biggest five-year swings in EBT: soared 954.35% in 2022 and later crashed 582.71% in 2023.
  • Neurocrine Biosciences' EBT stood at -$13.8 million in 2021, then soared by 954.35% to $117.9 million in 2022, then skyrocketed by 68.11% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then soared by 47.23% to $239.4 million in 2025.
  • The last three reported values for EBT were $239.4 million (Q4 2025), $291.8 million (Q3 2025), and $159.5 million (Q2 2025) per Business Quant data.